Imovax D.T. Adult (Diphtheria Toxoid, Tetanus Toxoid, Algeldrate)

The vaccine contains chemically inactivated forms of the diphtheria and tetanus toxins (toxoids). When injected, these toxoids are recognized as foreign by the immune system, prompting B‑cells to produce specific antibodies. The aluminum‑based adjuvant algeldrate amplifies this response, ensuring a strong and lasting protective immunity against the natural toxins.

The exact dose and schedule are determined by the prescribing healthcare professional. Typically, a single intramuscular or subcutaneous injection is administered for primary immunization, with booster doses given at recommended intervals to sustain immunity. Specific dosing may vary based on prior vaccination history and local guidelines.

Safety data for use during pregnancy and lactation are limited. The vaccine should only be administered when the potential benefit to the mother outweighs any theoretical risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss any concerns with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Imovax D.T. Adult. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Imovax D.T. Adult uses the same diphtheria and tetanus toxoid antigens found in other licensed vaccines, with algeldrate as an aluminum‑based adjuvant to boost immune response. Clinical efficacy and safety profiles are comparable to other EU‑approved diphtheria‑tetanus vaccines, though formulation differences such as adjuvant type may influence reactogenicity in some individuals.

The vaccine must be stored at 2‑8 °C (refrigerated). It should be kept in the original packaging, protected from light, and must never be frozen or shaken. During transport, maintain the cold‑chain conditions to preserve potency, and discard any vial that has been exposed to temperatures outside the recommended range.

Imovax D.T. Adult is administered by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm or the anterolateral thigh in adults. The injection site should be cleaned with an antiseptic, and the volume is drawn into a sterile syringe according to the vial’s labeling.

Serious adverse events are rare but may include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, seizures, and high‑grade fever. Any signs of a severe reaction—such as difficulty breathing, swelling of the face or throat, or neurological symptoms—require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, including the toxoids or the algeldrate adjuvant, should not receive it. It is also contraindicated in persons who have experienced a serious immediate hypersensitivity reaction to a previous dose of a diphtheria‑tetanus vaccine.